Dongwu Securities released a research report on April 25 stating that it gave Puri Ophthalmology (301239.SZ) a purchase rating. The main reasons for the rating include: 1) Cataract achieved rapid growth in 2023, and gross margins of various businesses inc

Dongwu Securities released a research report on April 25 stating that it gave Puri Ophthalmology (301239.SZ) a purchase rating. The main reasons for the rating include: 1) Cataract achieved rapid growth in 2023, and gross margins of various businesses increased simultaneously; 2) the non-profit margin of all businesses increased significantly in 2023, and all expense ratios declined; 3) 2024Q1 revenue increased slightly and profits declined. It is expected that the reason is that the cataract business continues to grow and the refractive optometry business is under pressure. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 26 07:34

A-share changes丨Q1 performance was under pressure, and Puri Ophthalmology once fell more than 11% to a record low

Glonghui, April 24 | Puri Ophthalmology (301239.SZ) once fell by more than 11%. The low was 45.23 yuan, a new low since listing, and its total market capitalization fell below 7 billion yuan. According to news, the company's main revenue for the first quarter was 676 million yuan, up 4.01% year on year; net profit to mother was 16.924,900 yuan, down 89.58% year on year. The company's net profit returned to mother last year was 268 million yuan, an increase of 1202.56% over the previous year. It can be seen from this that the company's performance in the first quarter of this year was clearly under pressure.

Gelonghui FinanceApr 24 14:49

The medical services sector opened and fell, and Puri Ophthalmology fell by more than 10%

The medical services sector opened and declined. As of press release, Puri Ophthalmology and Jinkai Biotech had fallen by more than 10%, while Hongbo Pharmaceutical and Huaxia Ophthalmology had followed suit.

Zhitong FinanceApr 24 09:37

Express News | Puri Ophthalmology: Net profit due to mother in 2023 was 268 million yuan, an increase of 1202.56% year-on-year

BreakingsApr 23 19:34

Express News | Puri Ophthalmology: Adhere to medical properties and build long-term value

BreakingsMar 7 17:41

Express News | Midday announcement: Funeng Oriental extends the validity period of the 2023 shareholders' meeting resolution to issue shares to specific targets

BreakingsMar 7 12:16